<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_cyclic" title="New Molecular Insights into the Inhibition of Dipeptidyl Peptidase-4 by Natural Cyclic Peptide Oxytocin" shortTitle="cyclic" author="Veera  C. S. R. Chittepu, Poonam Kalhotra, Tzayhri Osorio-Gallardo, Cristian Jiménez-Martínez, Raúl  René Robles-de la Torre, Tzayhri Gallardo-Velazquez, Guillermo Osorio-Revilla" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/1420-3049/24/21/3887/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Proteases	NNS	protease
are	VBP	be
associated	VBN	associate
with	IN	with
many	JJ	many
signaling	VBG	signal
biological	JJ	biological
pathways	NNS	pathway
,	,	,
and	CC	and
it	PRP	it
is	VBZ	be
has	VBZ	have
been	VBN	be
proven	VBN	prove
that	IN	that
the	DT	the
number	NN	number
of	IN	of
diseases	NNS	disease
like	IN	like
cancer	NN	cancer
,	,	,
HIV	NN	HIV
,	,	,
infectious	JJ	infectious
diseases	NNS	disease
,	,	,
and	CC	and
diabetes	NN	diabet
are	VBP	be
treated	VBN	treat
by	IN	by
inhibiting	VBG	inhibit
proteases	NNS	protease
.	.	.
</s>
<s type="decl">
Pharmaceutical	JJ	Pharmaceutical
companies	NNS	company
develop	VBP	develop
commercial	JJ	commercial
drugs	NNS	drug
to	TO	to
inhibit	VB	inhibit
aspartyl	NN	aspartyl
proteases	NNS	protease
,	,	,
serine	NN	serine
proteases	NNS	protease
,	,	,
and	CC	and
cysteine	NN	cysteine
proteases	NNS	protease
.	.	.
</s>
<s type="decl">
Among	IN	among
several	JJ	several
protease	NN	protease
inhibitors	NNS	inhibitor
,	,	,
serine	NN	serine
protease	NN	protease
inhibitors	NNS	inhibitor
received	VBD	receive
significant	JJ	significant
interest	NN	interest
in	IN	in
various	JJ	various
applications	NNS	application
focused	VBN	focus
mainly	RB	mainly
in	IN	in
therapeutics	NNS	therapeutics
.	.	.
</s>
<s type="decl">
Serine	NN	serine
protease	NN	protease
inhibitors	NNS	inhibitor
shown	VBN	show
in	IN	in
Table	NNP	Table
1	CD	1
,	,	,
are	VBP	be
used	VBN	use
in	IN	in
treating	VBG	treat
diseases	NNS	disease
like	IN	like
immune-related	JJ	immune-related
disorders	NNS	disorder
,	,	,
inflammatory	JJ	inflammatory
,	,	,
respiratory	JJ	respiratory
,	,	,
AIDS	NNP	AIDS
,	,	,
neurodegenerative	JJ	neurodegenerative
,	,	,
and	CC	and
metabolic	JJ	metabolic
disorders	NNS	disorder
.	.	.
</s>
</p>
<p>
<s type="decl">
Features	NNS	feature
like	IN	like
therapeutic	JJ	therapeutic
potential	NN	potential
,	,	,
good	JJ	good
binding	NN	binding
affinity	NN	affinity
,	,	,
low	JJ	low
toxicity	NN	toxicity
,	,	,
and	CC	and
quickly	RB	quickly
cleavable	JJ	cleavable
by	IN	by
proteolytic	JJ	proteolytic
enzymes	NNS	enzyme
,	,	,
make	VBP	make
cyclic	JJ	cyclic
peptides	NNS	peptide
potential	JJ	potential
future	JJ	future
therapeutics	NNS	therapeutics
.	.	.
</s>
<s type="decl">
Most	JJS	most
of	IN	of
the	DT	the
cyclic	JJ	cyclic
peptides	NNS	peptide
approved	VBN	approve
by	IN	by
the	DT	the
FDA	NNP	FDA
(	-LRB-	(
shown	VBN	show
in	IN	in
Table	NNP	Table
2	CD	2
)	-RRB-	)
are	VBP	be
used	VBN	use
in	IN	in
bacterial	JJ	bacterial
and	CC	and
fungal	JJ	fungal
infections	NNS	infection
,	,	,
oncology	NN	oncology
drugs	NNS	drug
,	,	,
gastrointestinal	JJ	gastrointestinal
disorders	NNS	disorder
,	,	,
and	CC	and
anemia	NN	anemia
.	.	.
</s>
<s type="decl">
Recently	RB	recently
,	,	,
cyclic	JJ	cyclic
peptides	NNS	peptide
were	VBD	be
proven	VBN	prove
to	TO	to
inhibit	VB	inhibit
HIV-1	NNP	HIV-1
protease	NN	protease
(	-LRB-	(
aspartyl	NN	aspartyl
proteases	NNS	protease
)	-RRB-	)
and	CC	and
elastase	NN	elastase
,	,	,
shedding	VBG	shed
light	NN	light
onto	IN	onto
the	DT	the
use	NN	use
of	IN	of
cyclic	JJ	cyclic
peptides	NNS	peptide
as	IN	as
protease	NN	protease
inhibitors	NNS	inhibitor
.	.	.
</s>
</p>
<p>
<s type="decl">
Phage	NN	phage
display	NN	display
technology	NN	technology
,	,	,
Incretin-based	NN	incretin-based
cyclic	JJ	cyclic
peptide	NN	peptide
,	,	,
cyclic	JJ	cyclic
peptides	NNS	peptide
from	IN	from
mRNA	NN	mRNA
display	NN	display
,	,	,
and	CC	and
split-pool	NN	split-pool
synthesis	NN	synthesis
are	VBP	be
some	DT	some
of	IN	of
the	DT	the
tools	NNS	tool
used	VBN	use
to	TO	to
develop	VB	develop
cyclic	JJ	cyclic
peptide	NN	peptide
compounds	NNS	compound
.	.	.
</s>
<s type="decl">
Recently	RB	recently
computer-aided	JJ	computer-aided
drug	NN	drug
design	NN	design
technologies	NNS	technology
like	IN	like
molecular	JJ	molecular
docking	NN	docking
simulations	NNS	simulation
are	VBP	be
applied	VBN	apply
to	TO	to
identify	VB	identify
,	,	,
design	VB	design
rationally	RB	rationally
(	-LRB-	(
called	VBN	call
as	IN	as
de	NNP	de
novo	NNP	Novo
developed	VBN	develop
)	-RRB-	)
,	,	,
and	CC	and
develop	VB	develop
cyclic	JJ	cyclic
peptide	NN	peptide
ligand	NN	ligand
as	IN	as
leads	NNS	lead
to	IN	to
therapeutic	JJ	therapeutic
drug	NN	drug
targets	NNS	target
of	IN	of
interest	NN	interest
.	.	.
</s>
<s type="decl">
Till	IN	till
today	NN	today
,	,	,
cyclic	JJ	cyclic
peptides	NNS	peptide
as	IN	as
therapeutics	NNS	therapeutics
in	IN	in
regulating	VBG	regulate
glucose	NN	glucose
metabolism	NN	metabolism
by	IN	by
inhibiting	VBG	inhibit
proteases	NNS	protease
have	VBP	have
not	RB	not
been	VBN	be
reported	VBN	report
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
diabetes	NNS	diabet
mellitus	NN	mellitus
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
Mexico	NNP	Mexico
,	,	,
approximately	RB	approximately
11.5	CD	11.5
million	CD	1000000
people	NNS	person
live	VBP	live
with	IN	with
diabetes	NNS	diabet
mellitus	NN	mellitus
(	-LRB-	(
DM	NNP	DM
)	-RRB-	)
,	,	,
which	WDT	which
is	VBZ	be
the	DT	the
main	JJ	main
leading	VBG	lead
cause	NN	cause
of	IN	of
acquired	VBN	acquire
blindness	NN	blindness
,	,	,
non-traumatic	JJ	non-traumatic
lower-limb	NN	lower-limb
amputations	NNS	amputation
,	,	,
and	CC	and
chronic	JJ	chronic
kidney	NN	kidney
failure	NN	failure
diseases	NNS	disease
.	.	.
</s>
<s type="decl">
Human	JJ	Human
dipeptidyl	NN	dipeptidyl
peptidase-4	NN	peptidase-4
(	-LRB-	(
DPP4	NNP	DPP4
)	-RRB-	)
is	VBZ	be
a	DT	a
serine	NN	serine
protease	NN	protease
,	,	,
well	RB	well
known	VBN	know
FDA-approved	NNP	FDA-approved
therapeutic	JJ	therapeutic
drug	NN	drug
target	NN	target
for	IN	for
regulating	VBG	regulate
blood	NN	blood
glucose	NN	glucose
metabolism	NN	metabolism
and	CC	and
treating	VBG	treat
diabetes	NNS	diabet
mellitus	NN	mellitus
.	.	.
</s>
<s type="decl">
Sitagliptin	NNP	Sitagliptin
,	,	,
Vildagliptin	NNP	Vildagliptin
,	,	,
Anagliptin	NNP	Anagliptin
,	,	,
Saxagliptin	NNP	Saxagliptin
,	,	,
and	CC	and
Alogliptin	NNP	Alogliptin
are	VBP	be
the	DT	the
main	JJ	main
clinically	RB	clinically
used	VBN	use
chemicals	NNS	chemical
for	IN	for
human	JJ	human
dipeptidyl	NN	dipeptidyl
peptidase-4	NN	peptidase-4
(	-LRB-	(
DPP4	NNP	DPP4
)	-RRB-	)
inhibition	NN	inhibition
despite	IN	despite
their	PRP$	their
side	NN	side
effects	NNS	effect
as	IN	as
pancreatitis	NN	pancreatitis
,	,	,
nausea	NN	nausea
,	,	,
and	CC	and
anemia	NN	anemia
.	.	.
</s>
<s type="decl">
It	PRP	it
is	VBZ	be
well	RB	well
known	VBN	know
that	IN	that
incretin	JJ	incretin
hormones	NNS	hormone
glucagon-like	JJ	glucagon-like
peptide	NN	peptide
1	CD	1
(	-LRB-	(
GLP-1	NNP	GLP-1
)	-RRB-	)
and	CC	and
glucose-dependent	JJ	glucose-dependent
insulinotropic	JJ	insulinotropic
polypeptide	NN	polypeptide
(	-LRB-	(
GIP	NNP	GIP
)	-RRB-	)
are	VBP	be
responsible	JJ	responsible
for	IN	for
insulin	NN	insulin
release	NN	release
and	CC	and
glucose	NN	glucose
regulation	NN	regulation
.	.	.
</s>
<s type="decl">
These	DT	this
hormones	NNS	hormone
are	VBP	be
inactivated	VBN	inactivate
by	IN	by
a	DT	a
serine	NN	serine
protease	NN	protease
human	JJ	human
dipeptidyl	NN	dipeptidyl
peptidase-4	NN	peptidase-4
(	-LRB-	(
DPP4	FW	DPP4
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Since	IN	since
natural	JJ	natural
cyclic	JJ	cyclic
peptides	NNS	peptide
are	VBP	be
proven	VBN	prove
to	TO	to
inhibit	VB	inhibit
various	JJ	various
proteases	NNS	protease
,	,	,
and	CC	and
to	TO	to
consider	VB	consider
the	DT	the
beneficial	JJ	beneficial
aspects	NNS	aspect
of	IN	of
cyclic	JJ	cyclic
peptides	NNS	peptide
in	IN	in
comparison	NN	comparison
to	IN	to
small	JJ	small
chemicals	NNS	chemical
,	,	,
like	IN	like
less	JJR	less
toxicity	NN	toxicity
,	,	,
no	DT	no
accumulation	NN	accumulation
in	IN	in
organs	NNS	organ
,	,	,
and	CC	and
rapid	JJ	rapid
degradation	NN	degradation
of	IN	of
peptides	NNS	peptide
,	,	,
we	PRP	we
hypothesized	VBD	hypothesize
that	IN	that
cyclic	JJ	cyclic
peptides	NNS	peptide
from	IN	from
natural	JJ	natural
sources	NNS	source
could	MD	could
be	VB	be
an	DT	a
alternative	JJ	alternative
source	NN	source
of	IN	of
therapeutics	NNS	therapeutics
to	TO	to
inhibit	VB	inhibit
serine	NN	serine
protease	NN	protease
DPP4	NNP	DPP4
for	IN	for
treatment	NN	treatment
of	IN	of
diabetes	NNS	diabet
mellitus	NN	mellitus
.	.	.
</s>
</p>
<p>
<s type="decl">
Among	IN	among
various	JJ	various
naturally	RB	naturally
occurring	VBG	occur
cyclic	JJ	cyclic
peptides	NNS	peptide
,	,	,
oxytocin	NN	oxytocin
(	-LRB-	(
natural	JJ	natural
cyclic	NN	cyclic
peptide	NN	peptide
)	-RRB-	)
was	VBD	be
chosen	VBN	choose
in	IN	in
this	DT	this
study	NN	study
to	TO	to
prove	VB	prove
our	PRP$	our
hypothesis	NN	hypothesis
that	IN	that
,	,	,
cyclic	JJ	cyclic
peptides	NNS	peptide
possess	VBP	possess
serine	NN	serine
protease	NN	protease
inhibition	NN	inhibition
activity	NN	activity
,	,	,
and	CC	and
specifically	RB	specifically
inhibit	VBP	inhibit
DPP4	NNP	DPP4
.	.	.
</s>
<s type="decl">
To	TO	to
demonstrate	VB	demonstrate
our	PRP$	our
hypothesis	NN	hypothesis
,	,	,
activity	NN	activity
atlas	NN	atla
and	CC	and
field-based	JJ	field-based
models	NNS	model
of	IN	of
DPP4	NNP	DPP4
inhibitors	NNS	inhibitor
from	IN	from
natural	JJ	natural
origin	NN	origin
were	VBD	be
utilized	VBN	utilize
to	TO	to
elucidate	VB	elucidate
molecular	JJ	molecular
insights	NNS	insight
of	IN	of
oxytocin	NN	oxytocin
peptide	NN	peptide
into	IN	into
DPP4	NNP	DPP4
inhibition	NN	inhibition
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
molecular	JJ	molecular
docking	NN	docking
simulations	NNS	simulation
were	VBD	be
used	VBN	use
to	TO	to
understand	VB	understand
the	DT	the
binding	NN	binding
poses	NNS	pose
and	CC	and
interacting	VBG	interact
residues	NNS	residue
responsible	JJ	responsible
for	IN	for
inhibitory	JJ	inhibitory
activity	NN	activity
.	.	.
</s>
<s type="decl">
Also	RB	also
,	,	,
the	DT	the
stability	NN	stability
of	IN	of
water	NN	water
molecules	NNS	molecule
at	IN	at
the	DT	the
binding	NN	binding
site	NN	site
of	IN	of
oxytocin	NN	oxytocin
was	VBD	be
studied	VBN	study
using	VBG	use
3D	NN	3D
reference	NN	reference
interaction	NN	interaction
site	NN	site
model	NN	model
(	-LRB-	(
3D-RISM	NNP	3D-RISM
)	-RRB-	)
to	TO	to
gain	VB	gain
deep	JJ	deep
insights	NNS	insight
into	IN	into
the	DT	the
binding	NN	binding
of	IN	of
the	DT	the
cyclic	JJ	cyclic
peptide	NN	peptide
at	IN	at
DPP4	NNP	DPP4
druggable	JJ	druggable
region	NN	region
.	.	.
</s>
<s type="decl">
Finally	RB	finally
,	,	,
fluorescence	NN	fluorescence
assay	NN	assay
was	VBD	be
used	VBN	use
to	TO	to
demonstrate	VB	demonstrate
the	DT	the
potential	JJ	potential
role	NN	role
of	IN	of
oxytocin	NN	oxytocin
as	IN	as
a	DT	a
DPP4	NNP	DPP4
inhibitor	NN	inhibitor
experimentally	RB	experimentally
.	.	.
</s>
</p>
</text>